January 16, 2022
1 min watch
Save
VIDEO: Encouraging data emerges from wet AMD trial
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
WAIKOLOA, Hawaii — At Hawaiian Eye 2022, Nancy Lurker, president and CEO of EyePoint Pharmaceuticals, discusses data from the Phase 1 DAVIO study of EYP-1901 for wet-AMD.
“We continue to be very encouraged by these data, and we look forward to showing additional OCT and BCVA data at Angiogenesis,” Lurker said.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.